Advanced Bionics v. MED-EL: Cochlear Implant Patent War Ends in Settlement
Advanced Bionics AG accused MED-EL of infringing two cochlear implant patents — US7317945B2 and US8422706B2 — through its SONNET 2 and RONDO 3 sound processors. Filed in the Delaware District Court in August 2024, the case resolved via a confidential settlement and was dismissed with prejudice after 287 days.
Cochlear Implant Giants Settle Delaware Patent Clash After Nine Months
Advanced Bionics AG, a leading cochlear implant manufacturer and subsidiary of Sonova, filed suit against Austrian rival MED-EL Elektromedizinische Gerate GmbH in the District of Delaware on 20 August 2024. The complaint alleged infringement of US7317945B2 and US8422706B2 — patents covering cochlear implant systems and related sound processing technology — through MED-EL’s SONNET 2, SONNET 2 EAS, and RONDO 3 sound processor products. The case was assigned to Judge Maryellen Noreika, a seasoned patent jurist in one of the most patent-active venues in the United States.
The case concluded on 3 June 2025 when the parties filed a joint stipulation of dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(ii), confirming that a settlement agreement had been reached resolving all claims. The dismissal was entered with prejudice, meaning Advanced Bionics is permanently barred from re-asserting the same claims against MED-EL arising from the same conduct. Each party agreed to bear its own legal costs, which typically signals a balanced commercial resolution rather than a capitulation by either side.
At 287 days, the resolution is notably swift for a multi-patent infringement action in Delaware, suggesting the parties may have entered negotiations early — possibly before extensive claim construction or discovery expenditure. The confidential settlement terms remain undisclosed, so whether a licensing arrangement, product design changes, or a cross-licensing component underlies the resolution is unknown from the public record. The with-prejudice dismissal does, however, foreclose any future litigation by Advanced Bionics on these specific patents as to these specific products.
Filing to Dismissed with Prejudice in 287 days
287 days — faster than the median patent case in Delaware, suggesting both parties moved toward resolution early
Settled and dismissed with prejudice: what the stipulation means for both parties
Rule 41(a)(1)(A)(ii) dismissal with prejudice explained
A joint stipulation under Rule 41(a)(1)(A)(ii) requires consent from all parties who have appeared, making it a consensual exit. The ‘with prejudice’ designation is the critical element: it carries the force of a final judgment on the merits, permanently extinguishing Advanced Bionics’ right to bring the same patent claims against MED-EL for the same accused products. This is a stronger closure mechanism than a without-prejudice dismissal and reflects the parties’ intent for finality.
Permanent bar on re-filingAdvanced Bionics surrenders future claims — but likely extracted value
By agreeing to a with-prejudice dismissal, Advanced Bionics has permanently closed the door on litigating US7317945B2 and US8422706B2 against MED-EL’s current accused products. However, this is consistent with a licensing deal: patentees routinely accept with-prejudice dismissals upon securing a royalty stream or lump-sum payment. The absence of fee-shifting suggests Advanced Bionics did not emerge empty-handed, though the specific commercial terms are not publicly disclosed.
Settlement value undisclosedMED-EL avoids invalidity ruling — but faces a permanent licence shadow
MED-EL escaped a court determination on patent validity and infringement, preserving its ability to argue both in any future dispute involving different products or different patent claims. However, the with-prejudice dismissal may be accompanied by a licence, meaning MED-EL’s SONNET 2 and RONDO 3 lines could carry ongoing royalty obligations. The each-party-bears-own-costs arrangement suggests MED-EL did not achieve a clear win on the merits, and its litigation investment was not recovered.
No invalidity ruling securedSettlement reinforces patent leverage in the cochlear implant duopoly
The cochlear implant market is dominated by a small number of players — Advanced Bionics (Sonova), MED-EL, and Cochlear Limited — making patent enforcement a key competitive lever. A swift settlement, rather than a full trial, preserves both parties’ freedom to compete while avoiding public disclosure of product designs or clinical data through discovery. For sector participants, the case signals that Advanced Bionics is actively enforcing its signal-processing IP portfolio and that Delaware remains the preferred enforcement venue.
Active portfolio enforcement signalFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Advanced Bionics AG | Company | Cochlear implant manufacturer (Sonova subsidiary) — holder of US7317945B2 and US8422706B2Search in Eureka ↗ |
| Defendant | MED-EL Elektromedizinische Gerate GmbH | Company | Austrian medical device maker; manufacturer of SONNET 2, RONDO 3, and SONNET 2 EAS cochlear systemsSearch in Eureka ↗ |
| Plaintiff counsel | Andrew Colin Mayo | Attorney | Counsel for Advanced Bionics AGSearch in Eureka ↗ |
| Plaintiff counsel | Steven J. Balick | Attorney | Counsel for Advanced Bionics AGSearch in Eureka ↗ |
| Plaintiff law firm | Ashby & Geddes PC | Law Firm | Representing Advanced Bionics AGSearch in Eureka ↗ |
| Defendant counsel | Grayson P. Sundermeir | Attorney | Counsel for MED-EL Elektromedizinische Gerate GmbHSearch in Eureka ↗ |
| Defendant counsel | Jeremy Douglas Anderson | Attorney | Counsel for MED-EL Elektromedizinische Gerate GmbHSearch in Eureka ↗ |
| Defendant law firm | Baker & Hostetler LLP | Law Firm | Representing MED-EL Elektromedizinische Gerate GmbHSearch in Eureka ↗ |
| Defendant law firm | Fish & Richardson PC | Law Firm | Representing MED-EL Elektromedizinische Gerate GmbHSearch in Eureka ↗ |
| Presiding judge | Judge Maryellen Noreika | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation confirms a settlement under Rule 41(a)(1)(A)(ii) with dismissal with prejudice — the parties’ own characterisation of the resolution. The with-prejudice designation is legally significant: it forecloses any future action by Advanced Bionics on the same claims against the same MED-EL products, functioning as a final adjudication on the merits without a judicial finding of infringement or validity. The equal cost allocation clause is consistent with a negotiated commercial resolution rather than a capitulation, though the underlying settlement terms remain confidential.
US7317945B2 & US8422706B2 — Cochlear Implant Signal Processing Patents
US7317945B2 (application no. US10/712078) and US8422706B2 (application no. US12/879603) are US utility patents covering technology in the cochlear implant domain, specifically relating to sound processing and signal transmission architectures used in externally worn sound processors. The patents were asserted against MED-EL’s externally worn SONNET 2, SONNET 2 EAS, and RONDO 3 processor units — core commercial products in MED-EL’s cochlear implant portfolio — suggesting the claimed inventions cover foundational processing approaches rather than peripheral features.
For cochlear implant manufacturers and hearing technology developers, these patents represent strategically significant IP assets because sound processing is the central differentiator in implant performance and patient outcomes. Advanced Bionics’ decision to assert both patents simultaneously against multiple MED-EL product lines signals that it views these as broad-coverage foundational patents. Competitors developing next-generation behind-the-ear or off-the-ear sound processors should conduct thorough FTO analysis against both patent families, particularly given that the settlement — rather than invalidation — leaves both patents fully intact and enforceable.
Should your team run an FTO analysis against US7317945B2 and US8422706B2?
Any company designing cochlear implant sound processors, external audio processors for active implants, or signal processing algorithms used in hearing implant systems should treat these two patents as live FTO risks. The settlement, entered with prejudice, means neither patent was invalidated in this proceeding. Advanced Bionics has now demonstrated willingness to assert both patents in US federal court against a major international competitor — a clear signal of active enforcement intent.
PatSnap Eureka’s FTO Search Agent allows your R&D and IP teams to map the claim scope of US7317945B2 and US8422706B2 against your product architecture, identify prior art that could form the basis of an IPR petition, and monitor the Advanced Bionics patent portfolio for continuation filings or related family members. With both patents surviving this litigation intact, a structured FTO review is a proportionate and commercially prudent step before launching or iterating any cochlear sound processor product.
Run a freedom-to-operate analysis on US7317945B2 to assess your product’s exposure
Run FTO in Eureka →Similar Cochlear Implant & Hearing Technology Patent Cases in US Federal Courts
Cases involving cochlear implant and hearing device patents litigated in Delaware and other US district courts, including Advanced Bionics, MED-EL, and Cochlear Limited disputes.
What this case signals for the cochlear implant IP landscape
Advanced Bionics’ willingness to file and settle swiftly in Delaware signals calculated portfolio leverage in a tightly contested medtech market.
Delaware remains the go-to venue for high-stakes medtech patent disputes
Advanced Bionics chose the District of Delaware — home to Judge Noreika and a deep bench of patent-experienced jurists — for a cross-border infringement action against an Austrian defendant. For IP teams at medical device companies, this confirms Delaware’s continued primacy for patent enforcement strategy, particularly where foreign manufacturers distribute products in the US.
Sound processor patents are active enforcement assets in cochlear implant competition
The assertion of two separate patents (US7317945B2 and US8422706B2) against multiple MED-EL product lines — SONNET 2, RONDO 3, SONNET 2 EAS — illustrates a portfolio enforcement approach. R&D and IP teams at hearing implant companies should map competing signal-processing and sound processor patent families to anticipate freedom-to-operate risks before next-generation product launches.
Advanced v MED-EL — key questions answered
The case was dismissed with prejudice on 3 June 2025 pursuant to a joint stipulation of dismissal under Rule 41(a)(1)(A)(ii), following a confidential settlement agreement between the parties. Each party agreed to bear its own costs and attorneys’ fees. No judicial finding on patent infringement or validity was issued.
Advanced Bionics asserted US7317945B2 (application no. US10/712078) and US8422706B2 (application no. US12/879603), both covering cochlear implant and sound processing technology. These were asserted against MED-EL’s SONNET 2, SONNET 2 EAS, and RONDO 3 sound processor product lines.
A dismissal with prejudice functions as a final adjudication on the merits and permanently bars Advanced Bionics from re-filing the same claims against MED-EL for the same accused conduct and products. Advanced Bionics cannot re-litigate infringement of US7317945B2 and US8422706B2 as asserted in this action. It could potentially assert related but distinct claims on different products or patent family members, subject to applicable legal doctrines.
Yes. Because the case settled and was dismissed without any court ruling on validity or infringement, both US7317945B2 and US8422706B2 remain fully enforceable. No inter partes review or other invalidity proceeding outcome affecting these patents is reflected in the case data. Companies in the cochlear implant or hearing technology space should treat both patents as live enforcement risks.
Delaware is a preferred venue for patent enforcement due to its experienced patent judiciary, well-developed local patent rules, and established case law. Judge Maryellen Noreika, assigned to this case, is among the most experienced patent trial judges in the district. Delaware’s receptiveness to cases involving foreign defendants with US product distribution makes it a strategically rational choice for cross-border patent assertions like this one.
PatSnap Eureka searches patents and litigation data to answer instantly.